BCMA-targeting CAR-T for relapsed/refractory multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new kind of immunotherapy called CAR-T that targets BCMA on myeloma cells. It is for people whose multiple myeloma has come back after or not responded to at least two previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your multiple myeloma has come back or is not responding after at least two prior treatments, and you have tried drugs like proteasome inhibitors and immunomodulators.
- You are generally able to take care of yourself (ECOG score 0-2).
- Your heart, kidneys, liver, and lungs are working well enough (based on standard tests).
- You do not have an active serious infection, hepatitis B or C, or HIV.
- You have not had a stroke, seizure, or other major brain condition in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (BCMA and FcRL5) on myeloma cells. It is for people whose myeloma has returned or not responded to other treatments.
This trial tests a new treatment using your own immune cells, modified to find and attack a protein called BCMA on myeloma cells. It is for people whose multiple myeloma has come back or not responded to at least three prior treatments.
This trial tests a new kind of immunotherapy that uses your own immune cells, called CAR-T cells, to target two specific markers (BCMA and GPRC5D) found on myeloma cells. It's for people whose multiple myeloma has come back or stopped responding to earlier treatments.
Hear when a new Multiple Myeloma Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.